BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 8313357)

  • 1. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.
    Habeck LL; Leitner TA; Shackelford KA; Gossett LS; Schultz RM; Andis SL; Shih C; Grindey GB; Mendelsohn LG
    Cancer Res; 1994 Feb; 54(4):1021-6. PubMed ID: 8313357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.
    Mendelsohn LG; Shih C; Schultz RM; Worzalla JF
    Invest New Drugs; 1996; 14(3):287-94. PubMed ID: 8958184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase.
    Sanghani SP; Moran RG
    Biochemistry; 1997 Aug; 36(34):10506-16. PubMed ID: 9265631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
    Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
    Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
    Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
    Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of glycinamide ribonucleotide formyltransferase and other folate enzymes by homofolate polyglutamates in human lymphoma and murine leukemia cell extracts.
    Thorndike J; Gaumont Y; Kisliuk RL; Sirotnak FM; Murthy BR; Nair MG; Piper JR
    Cancer Res; 1989 Jan; 49(1):158-63. PubMed ID: 2521177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
    Galivan J; Nimec Z; Rhee M; Boschelli D; Oronsky AL; Kerwar SS
    Cancer Res; 1988 May; 48(9):2421-5. PubMed ID: 2965613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase.
    Baldwin SW; Tse A; Gossett LS; Taylor EC; Rosowsky A; Shih C; Moran RG
    Biochemistry; 1991 Feb; 30(7):1997-2006. PubMed ID: 1993209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.
    Zhao R; Gao F; Babani S; Goldman ID
    Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
    Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antifolate activity of 5-methyl-5,10-dideaza analogues of aminopterin and folic acid and an alternative synthesis of 5,10-dideazatetrahydrofolic acid, a potent inhibitor of glycinamide ribonucleotide formyltransferase.
    Piper JR; McCaleb GS; Montgomery JA; Kisliuk RL; Gaumont Y; Thorndike J; Sirotnak FM
    J Med Chem; 1988 Nov; 31(11):2164-9. PubMed ID: 3184124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein structure-based design, synthesis, and biological evaluation of 5-thia-2,6-diamino-4(3H)-oxopyrimidines: potent inhibitors of glycinamide ribonucleotide transformylase with potent cell growth inhibition.
    Varney MD; Palmer CL; Romines WH; Boritzki T; Margosiak SA; Almassy R; Janson CA; Bartlett C; Howland EJ; Ferre R
    J Med Chem; 1997 Aug; 40(16):2502-24. PubMed ID: 9258357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase.
    Boritzki TJ; Barlett CA; Zhang C; Howland EF
    Invest New Drugs; 1996; 14(3):295-303. PubMed ID: 8958185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol.
    Mendelsohn LG; Gates SB; Habeck LL; Shackelford KA; Worzalla J; Shih C; Grindey GB
    Adv Enzyme Regul; 1996; 36():365-81. PubMed ID: 8869756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid.
    Zhang Y; Desharnais J; Marsilje TH; Li C; Hedrick MP; Gooljarsingh LT; Tavassoli A; Benkovic SJ; Olson AJ; Boger DL; Wilson IA
    Biochemistry; 2003 May; 42(20):6043-56. PubMed ID: 12755606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
    Habeck LL; Mendelsohn LG; Shih C; Taylor EC; Colman PD; Gossett LS; Leitner TA; Schultz RM; Andis SL; Moran RG
    Mol Pharmacol; 1995 Aug; 48(2):326-33. PubMed ID: 7651366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
    Smith SG; Lehman NL; Moran RG
    Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Side chain modified 5-deazafolate and 5-deazatetrahydrofolate analogues as mammalian folylpolyglutamate synthetase and glycinamide ribonucleotide formyltransferase inhibitors: synthesis and in vitro biological evaluation.
    Rosowsky A; Forsch RA; Reich VE; Freisheim JH; Moran RG
    J Med Chem; 1992 May; 35(9):1578-88. PubMed ID: 1578484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway.
    Cheng H; Chong Y; Hwang I; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
    Bioorg Med Chem; 2005 May; 13(10):3577-85. PubMed ID: 15848770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.